Literature DB >> 2997568

Serotonergic agonists stimulate inositol lipid metabolism in rabbit platelets.

M Schächter, P P Godfrey, M C Minchin, S J McClue, M M Young.   

Abstract

The metabolism of inositol phospholipids in response to serotonergic agonists was investigated in rabbit platelets. In platelets prelabelled with [3H]-inositol, in a medium containing 10 mM LiCl which blocks the enzyme inositol-1-phosphatase, 5-hydroxytryptamine (5-HT) caused a dose-dependent accumulation of inositol phosphates (IP). This suggests a phospholipase-C-mediated breakdown of phosphoinositides. Ketanserin, a selective 5-HT2 antagonist, was a potent inhibitor of the 5-HT response, with a Ki of 28 nM, indicating that 5-HT is activating receptors of the 5-HT2 type in the platelet. Lysergic acid diethylamide (LSD) and quipazine also caused dose-related increases in inositol phosphate levels, though these were considerably less than those produced by 5-HT. These results show that relatively small changes in phosphoinositide metabolism induced by serotonergic agonists can be investigated in the rabbit platelet, and this cell may therefore be a useful model for the study of some 5-HT receptors.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2997568     DOI: 10.1016/0024-3205(85)90484-9

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  3 in total

1.  Potentiation of ADP-induced aggregation in human platelet-rich plasma by 5-hydroxytryptamine and adrenaline.

Authors:  D M Vanags; S E Rodgers; E M Duncan; J V Lloyd; F Bochner
Journal:  Br J Pharmacol       Date:  1992-08       Impact factor: 8.739

2.  Central serotonin receptors: effector systems, physiological roles and regulation.

Authors:  P J Conn; E Sanders-Bush
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

3.  Dose-dependent inhibition of phosphoinositide metabolism in human platelets by aspirin in vitro and in vivo.

Authors:  P P Godfrey; F Bochner; D G Grahame-Smith
Journal:  Br J Clin Pharmacol       Date:  1986-10       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.